Vancomycin is a glycopeptide antibiotic commonly used in the management of methicillin-resistant Staphylococcus aureus infection. The recent increase in prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin has prompted experts to advocate for higher target trough serum concentrations. This study aimed to evaluate the potential consequences of more aggressive vancomycin therapy, by examining the association between higher serum concentrations and acute kidney injury (AKI) in a population of critically ill patients. We collected data for all patients who received vancomycin over a five-year period and evaluated the prevalence of new-onset AKI using the Risk, Injury, Failure, Loss and End-stage (RIFLE) kidney disease criteria. One-hundred and fifty-nine patients provided complete data, with 8.8% manifesting new onset AKI while receiving vancomycin. The median age was 57 (44 to 68) years, while the median trough serum concentration was 16 (10 to 19) mg/l. Multivariate logistic regression analysis identified mean trough concentration (OR=1.174, P=0.024), APACHE II score (OR=1.141, P=0.012) and simultaneous aminoglycoside prescription (OR=18.896, P=0.002) as significant predictors of AKI. These data suggest higher trough vancomycin serum concentrations are associated with greater odds of AKI in the critically ill.
Vancomycin is a glycopeptide antibiotic commonly used to treat methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci infections in the critically ill 1, 2 . Recently, there has been an increase in the prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin, with serum concentrations <10 mg/l associated with the emergence of vancomycinresistant Staphylococcus aureus 3 . Subsequently, current consensus guidelines now recommend a target serum vancomycin trough concentration between 15 and 20 mg/l 4 . Given the historical target was 5 to 10 mg/l 5 , there is a relative paucity of data examining the effect of more aggressive drug exposures on the incidence of vancomycin-associated adverse effects, especially in the critically ill.
Vancomycin-associated nephrotoxicity has been reported in up to 40% of recipients, although the exact factors predictive of acute kidney injury (AKI) in this setting are still debated 2 . Current data suggests that higher daily doses, higher trough serum concentrations and increased duration of therapy are associated with nephrotoxicity 6, 7 . Given the baseline risk of developing nephrotoxicity is between 36% and 67% in the critically ill (depending on the definition employed) 8 , there is an imperative to more specifically identify which factors are linked with vancomycin-associated AKI, in order to optimise clinical efficacy and safety when prescribing this agent. As such, our aim was to examine the incidence of new-onset AKI in critically ill patients receiving vancomycin, admitted to a tertiary-referral hospital over a five-year period. Furthermore, we aimed to evaluate independent risk factors predictive of AKI in this cohort, with a view to informing future dosing practice. Baseline variables included age, sex, weight, date of admission, admission diagnosis, APACHE II score 9 and treatment received while in ICU. Information pertaining to patient comorbidities was also collected. Patients were excluded from further analysis if they were less than 18 years of age, had a baseline serum creatinine concentration >176.8 µmol/l (2 mg/dl) 10 or were receiving renal replacement therapy at the time of commencing vancomycin therapy. Vancomycin doses, serum concentrations and baseline renal function for at least two days prior to commencement of therapy were also required for inclusion in analysis. Local protocol dictates that vancomycin dose is determined by actual body weight on admission. Weight was not recorded for all patients; it was assumed in such cases that protocol was followed.
Methods
In those patients receiving vancomycin by intermittent infusion, trough serum concentrations were obtained within 48 hours of commencing therapy, after a minimum of three doses 11 . Thereafter, trough serum concentrations were collected 30 minutes prior to the next dose. If a patient received vancomycin by continuous infusion, concentrations were collected at random intervals, but not before 18 hours had elapsed since prior dose alteration. The choice of infusion method was ultimately dictated by individual clinician preference, though the standard unit protocol was intermittent infusion during the study period. Dosing was subsequently adjusted to achieve a vancomycin concentration in the desired range. Where multiple serum vancomycin concentrations were available, mean trough concentrations were calculated for use in subsequent analysis. All available vancomycin concentrations were included. For those patients who developed AKI, only levels obtained prior to this point were retained in analysis.
AKI was determined using the Risk, Injury, Failure, Loss, End-stage (RIFLE) kidney disease 12 criteria, such that a patient was deemed to have AKI if they showed a sustained increase in serum creatinine (>1.5 times baseline) for greater than 48 hours duration. Urine output, estimated glomerular filtration rate and calculated creatinine clearance were not used as a measure of renal function, as changes from baseline creatinine are adequately sensitive in detecting AKI 13, 14 . Creatinine serum concentrations were recorded for the duration of ICU admission, though only values obtained during vancomycin administration were included in the assessment of vancomycin-associated AKI.
Vasopressor data and simultaneous nephrotoxic agent administration (including angiotensin converting enzyme inhibitors, diuretics, aminoglycosides, amphotericin, iodinated contrast agents, acyclovir, cyclosporin and non-steroidal anti-inflammatory drugs) were collected as potential confounding variables. Continuous data are reported as mean ± SD where normally distributed and median (IQR) where non-normally distributed. Categorical data are presented as counts (%). Univariate comparisons were made between those with and without new-onset AKI, utilising parametric and nonparametric tests of significance as appropriate. Backwards, stepwise logistic regression analysis was used to ascertain a parsimonious model identifying predictors of AKI. Goodness-of-fit was assessed by the Hosmer and Lemeshow statistic and the Nagelkerke R 2 index. Receiver operating characteristic (ROC) curves were used to identify thresholds for AKI. A P <0.05 was considered as statistically significant. Analysis was performed in SPSS version 20.0 (IBM Corp., Armonk, NY, USA). 
Patients receiving vancomycin in ICU

Results
During the study period, vancomycin was prescribed for 303 patients, of whom 251 received it for >96 hours. A further 93 patients were excluded from data extraction, reasons for which are presented in Figure 1 . One hundred and fifty-eight patients were included in the final analysis.
The median age was 57 (43.75 to 68.25) years, mean APACHE II score 21.32±7.40 and 65.8% (104 of 158) were male. Median vancomycin treatment time was 158 (120 to 234) hours. The primary method of vancomycin administration was intermittent dosing (145 of 158, 91.8%), while two patients (1.3%) received vancomycin by continuous infusion. Eleven patients (7%) received vancomycin by both continuous and intermittent infusion. Fourteen patients (8.9%) developed new-onset AKI following vancomycin exposure. Twelve (7.6%) patients died in ICU. There was simultaneous use of nephrotoxic agents in 70.9% (112 of 158). These characteristics are summarised in Table 1 .
There was no significant difference in the duration of vancomycin therapy amongst those patients who developed AKI (175.5 [127.75 to 374.75]) compared to those who did not (158 [117.75 to 213.75]). However, patients with AKI were more likely to have sepsis (64.3% versus 36.1%, P=0.047) or ischaemic heart disease (35.7% versus 11.1%, P=0.023) as their primary admission diagnosis. Table 2 summarises the key differences between the AKI and non-AKI groups.
The serum trough concentration threshold with the greatest sensitivity and specificity for AKI was 16.5 mg/l by receiver operating characteristic analysis (sensitivity=0.93, specificity=0.60, Youden's index=0.53, area under the curve=0.815). Backwards logistic regression analysis identified mean trough serum vancomycin concentration (OR=1.174, P=0.024) and APACHE II score (OR=1.141, P=0.012) as significant independent positive predictors of AKI. In addition, simultaneous administration of an aminoglycoside was the only nephrotoxin identified as being predictive of new-onset AKI (OR=18.896, P=0.002). Goodness-of-fit was adequate (Hosmer and Lemeshow X 2 =1.583, df=8, P=0.991, Nagelkerke R 2 =0.492). Table 3 summarises the regression analysis.
Discussion
In this cohort of critically ill patients treated with vancomycin for longer than 96 hours, new-onset AKI was noted in approximately one out of every ten patients. Higher peak, mean and initial trough vancomycin concentrations were associated with AKI in univariate analysis, although only the mean concentration was an independent predictor in regression modelling (OR=1.174, P=0.024). This means that for every 1 mg/l increase in mean trough serum vancomycin concentration, there is a 17.4% increase in the odds of newonset AKI.
These findings are consistent with Lodise et al 10 , who noted that the mean initial vancomycin trough value was significantly higher amongst patients who had nephrotoxicity. Similarly, Pritchard et al 6 identified an increased prevalence of vancomycin toxicity in patients with higher serum vancomycin trough values. Interestingly, Pritchard et al 6 also identified duration of therapy greater than 7 days as an independent risk factor for nephrotoxicity. In our study, duration of therapy was non-significantly greater in the new-onset AKI group, although the sample size is not sufficient to further explore this observation.
Interestingly, all 14 patients who had new-onset AKI in this cohort had mean trough serum vancomycin concentrations >15 mg/l. Furthermore, receiver operating characteristic analysis identified 16.5 mg/l as the concentration with the greatest sensitivity and specificity for new onset AKI. This suggests that, although greater trough serum vancomycin concentrations may be more efficacious 11, 15 , this may be at the expense of more AKI in a small number of patients. Prospective studies evaluating patients with serum vancomycin concentrations above 15 mg/l, compared to those below 15 mg/l, would further elucidate this finding.
Our study also suggests that concurrent use of aminoglycosides and vancomycin increases the risk of newonset AKI 11, [15] [16] [17] . Specifically, there were 18.89 (P=0.002) times greater odds of developing AKI in those patients who received aminoglycosides and vancomycin simultaneously. Although it is standard practice to use single daily doses at our institution, we did not collect data on the type or duration of aminoglycoside therapy in this cohort. Rather, we only determined if the patient had received aminoglycosides of any type, at any time, during their admission. As such, the precise impact of aminoglycosides cannot be determined accurately, although a relationship appears to exist, mandating further research.
We included APACHE II in the multivariate model to account for illness severity 9 . The mean APACHE II score in patients who developed AKI was non-significantly higher in univariate analysis (25.86 versus 20.88, P=0.107). Nevertheless, APACHE II was identified as a significant independent risk factor in regression modelling. In this case, every one-unit increase in APACHE II score is associated with a 14.1% increase in the odds of AKI. This is perhaps not surprising, although it does suggest that those patients with greater illness severity are at higher risk of AKI in the setting of vancomycin therapy. Moreover, it highlights the value of careful therapeutic drug monitoring and tracking of renal function in such patients. Similarly, there was a significantly higher rate of AKI in patients who were diagnosed with sepsis at the time of admission. However, this was not an independent predictor of AKI in our multivariate model, a finding contrary to other studies 18 . Patients with sepsis have a larger vancomycin volume of distribution (up to twice that of normal) and decreased vancomycin renal clearance, as compared to the general population 19 . This has the two-fold effect of both increasing daily dose requirements and increasing the duration of exposure in patients already vulnerable to AKI. Given vancomycin clearance is primarily renal 20 , vancomycin clearance decreases in a linear fashion with reduced creatinine clearance. This serves to increase the half-life from between three and nine hours (in healthy adults) 21 to up to 180 hours in those with severe renal failure 20 . As such, we postulate that having a diagnosis of sepsis would likely contribute to new-onset AKI with vancomycin therapy, notwithstanding the results of our multivariate analysis. No significant increase in AKI was seen amongst patients receiving vancomycin and inotropes, a finding disparate with previous reports 22, 23 . Furthermore, despite AKI being an established independent risk factor for increased mortality 24,25 , we were not able to demonstrate this. There was, however, a non-significant suggestion that there was an increased mortality in those with new-onset AKI in univariate analysis. These observations, seemingly at odds with current literature, are likely attributable to the low incidence of AKI in our study cohort.
This study is limited by its retrospective design, in that causality cannot be determined. Furthermore, similar to other literature in this area, it is difficult to precisely define the time course of changes in renal function. As such, it is conceivable that the higher vancomycin concentrations observed in AKI patients is a reflection of 'subclinical' renal impairment, albeit not initially significant enough to cause a rise in plasma creatinine concentrations. Additionally, we cannot account for all potential confounders, only those that were collected and included in multivariate analysis. Ideally, a prospective trial would confirm these results. We also acknowledge that the sample size may not be sufficient to identify all predictive factors with absolute certainty, especially as we have reported a lower rate of AKI compared with previous literature 2 . It should be noted that we excluded patients with a baseline creatinine greater than 176.8 µmol/l 10 -a group at high risk of developing AKI. As such, these data cannot be generalised to all patients in the ICU. Furthermore, we did not include any long-term morbidity and mortality data in the study, so we are unable to determine the lasting significance of these findings.
Conclusion
In conclusion, these data confirm that higher trough serum vancomycin concentrations are associated with greater odds *Age was re-categorised as an ordinal scale in ten-year increments; odds ratio per 10-year increment increase in age. †The OR is the odds ratio of AKI in a female versus that of a male i.e. females have a 0.165 lower odds of AKI than that of males. ‡Dichotomous variables are expressed as the OR of having or receiving the nominated variable versus not. AKI=acute kidney injury, ACEi=angiotensin-2 converting enzyme inhibitor, ARB=angiotensin-2 receptor blocker.
of new-onset AKI in the critically ill, although absolute cause and effect remains uncertain. Our findings also underscore the importance of strict therapeutic drug monitoring and dose adjustment of vancomycin [26] [27] [28] , particularly with the significant alterations in pharmacokinetics commonly encountered in these patients. This is especially important in those with higher baseline illness severity, as this appears to be an important risk factor for new-onset AKI in this setting. As this subgroup of patients often require empirical antibacterial therapy, use of vancomycin therapeutic drug monitoring should be considered mandatory, with the avoidance of supratherapeutic concentrations. Future prospective research should now systematically evaluate the impact of aggressive vancomycin exposure on both clinical efficacy and toxicity.
